0

Close
 
Upcoming Allied Market Research
2023
Cardiopulmonary Auto-transfusion System Market

Cardiopulmonary Auto-transfusion System Market

by Product (On-Pump Transfusion Device, Off-Pump Transfusion Device) and by End User (Hospitals, Ambulatory Surgical Centers, Cardiac Research Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A03608
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cardiopulmonary Auto-transfusion System Market

Request Now !

Cardiopulmonary auto-transfusion system is a device that provides autologous blood during surgical procedures. After observing the negative effects of using allogenic blood transfusions, surgeons gradually adopt the auto-transfusion system in a bid to eliminate complications and the spread of diseases through cardiac surgeries.

Increase in prevalence of cardiac diseases, growth in geriatric population, and awareness about advanced treatment drive the market growth. In addition, rise in healthcare expenditure fuels the growth of the cardiopulmonary auto-transfusion system market. However, high cost is expected to restrain the market growth. Increase in demand for cardiopulmonary auto-transfusion system in emerging nation is anticipated to create new opportunities during the forecast period.

The cardiopulmonary auto-transfusion system market is segmented on the basis of product, end user, and geography. By product, the market is classified as on-pump transfusion device and off-pump transfusion device. By end user, the market is categorized as hospitals, ambulatory surgical centers, and cardiac research centers. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to determine various products available in the market.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.

 Cardiopulmonary Auto-transfusion System Market Report Highlights

Aspects Details
By Product
  • On-Pump Transfusion Device
  • Off-Pump Transfusion Device
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Research Centers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Latin America, Middle East, Africa)
Key Market Players Wandong Health Sources, LivaNova PLC, Medtronic Plc., Haemonetics Corporation, Stryker Corporation, Global Blood Resources, Terumo Interventional Systems, Atrium Medical Corp., Fresenius GROUP, Redax S.p.A
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. On-Pump Transfusion Device

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Off-Pump Transfusion Device

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ambulatory Surgical Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cardiac Research Centers

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Cardiopulmonary Auto-transfusion System Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Cardiopulmonary Auto-transfusion System Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Cardiopulmonary Auto-transfusion System Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Cardiopulmonary Auto-transfusion System Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Cardiopulmonary Auto-transfusion System Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Cardiopulmonary Auto-transfusion System Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Cardiopulmonary Auto-transfusion System Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Cardiopulmonary Auto-transfusion System Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Cardiopulmonary Auto-transfusion System Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Cardiopulmonary Auto-transfusion System Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Cardiopulmonary Auto-transfusion System Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Cardiopulmonary Auto-transfusion System Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Cardiopulmonary Auto-transfusion System Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Cardiopulmonary Auto-transfusion System Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Cardiopulmonary Auto-transfusion System Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Cardiopulmonary Auto-transfusion System Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Cardiopulmonary Auto-transfusion System Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Cardiopulmonary Auto-transfusion System Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Cardiopulmonary Auto-transfusion System Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Cardiopulmonary Auto-transfusion System Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Cardiopulmonary Auto-transfusion System Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Cardiopulmonary Auto-transfusion System Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Cardiopulmonary Auto-transfusion System Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Cardiopulmonary Auto-transfusion System Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Cardiopulmonary Auto-transfusion System Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Haemonetics Corporation

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Medtronic Plc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. LivaNova PLC

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Fresenius GROUP

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Terumo Interventional Systems

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Wandong Health Sources

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Redax S.p.A

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Global Blood Resources

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Atrium Medical Corp.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Stryker Corporation

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR ON-PUMP TRANSFUSION DEVICE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR OFF-PUMP TRANSFUSION DEVICE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR CARDIAC RESEARCH CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. U.S. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 13. U.S. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. CANADA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 15. CANADA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. ITALY CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. ITALY CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. UK CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. UK CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. CHINA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. CHINA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. INDIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. INDIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. UAE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. UAE CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. HAEMONETICS CORPORATION: KEY EXECUTIVES
  • TABLE 72. HAEMONETICS CORPORATION: COMPANY SNAPSHOT
  • TABLE 73. HAEMONETICS CORPORATION: OPERATING SEGMENTS
  • TABLE 74. HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 75. HAEMONETICS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. MEDTRONIC PLC.: KEY EXECUTIVES
  • TABLE 77. MEDTRONIC PLC.: COMPANY SNAPSHOT
  • TABLE 78. MEDTRONIC PLC.: OPERATING SEGMENTS
  • TABLE 79. MEDTRONIC PLC.: PRODUCT PORTFOLIO
  • TABLE 80. MEDTRONIC PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. LIVANOVA PLC: KEY EXECUTIVES
  • TABLE 82. LIVANOVA PLC: COMPANY SNAPSHOT
  • TABLE 83. LIVANOVA PLC: OPERATING SEGMENTS
  • TABLE 84. LIVANOVA PLC: PRODUCT PORTFOLIO
  • TABLE 85. LIVANOVA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. FRESENIUS GROUP: KEY EXECUTIVES
  • TABLE 87. FRESENIUS GROUP: COMPANY SNAPSHOT
  • TABLE 88. FRESENIUS GROUP: OPERATING SEGMENTS
  • TABLE 89. FRESENIUS GROUP: PRODUCT PORTFOLIO
  • TABLE 90. FRESENIUS GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. TERUMO INTERVENTIONAL SYSTEMS: KEY EXECUTIVES
  • TABLE 92. TERUMO INTERVENTIONAL SYSTEMS: COMPANY SNAPSHOT
  • TABLE 93. TERUMO INTERVENTIONAL SYSTEMS: OPERATING SEGMENTS
  • TABLE 94. TERUMO INTERVENTIONAL SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 95. TERUMO INTERVENTIONAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. WANDONG HEALTH SOURCES: KEY EXECUTIVES
  • TABLE 97. WANDONG HEALTH SOURCES: COMPANY SNAPSHOT
  • TABLE 98. WANDONG HEALTH SOURCES: OPERATING SEGMENTS
  • TABLE 99. WANDONG HEALTH SOURCES: PRODUCT PORTFOLIO
  • TABLE 100. WANDONG HEALTH SOURCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. REDAX S.P.A: KEY EXECUTIVES
  • TABLE 102. REDAX S.P.A: COMPANY SNAPSHOT
  • TABLE 103. REDAX S.P.A: OPERATING SEGMENTS
  • TABLE 104. REDAX S.P.A: PRODUCT PORTFOLIO
  • TABLE 105. REDAX S.P.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. GLOBAL BLOOD RESOURCES: KEY EXECUTIVES
  • TABLE 107. GLOBAL BLOOD RESOURCES: COMPANY SNAPSHOT
  • TABLE 108. GLOBAL BLOOD RESOURCES: OPERATING SEGMENTS
  • TABLE 109. GLOBAL BLOOD RESOURCES: PRODUCT PORTFOLIO
  • TABLE 110. GLOBAL BLOOD RESOURCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. ATRIUM MEDICAL CORP.: KEY EXECUTIVES
  • TABLE 112. ATRIUM MEDICAL CORP.: COMPANY SNAPSHOT
  • TABLE 113. ATRIUM MEDICAL CORP.: OPERATING SEGMENTS
  • TABLE 114. ATRIUM MEDICAL CORP.: PRODUCT PORTFOLIO
  • TABLE 115. ATRIUM MEDICAL CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. STRYKER CORPORATION: KEY EXECUTIVES
  • TABLE 117. STRYKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 118. STRYKER CORPORATION: OPERATING SEGMENTS
  • TABLE 119. STRYKER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 120. STRYKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET
  • FIGURE 3. SEGMENTATION CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET
  • FIGURE 11. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR ON-PUMP TRANSFUSION DEVICE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR OFF-PUMP TRANSFUSION DEVICE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET SEGMENTATION, BY BY END USER
  • FIGURE 15. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET FOR CARDIAC RESEARCH CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: CARDIOPULMONARY AUTO-TRANSFUSION SYSTEM MARKET
  • FIGURE 24. Top player positioning, 2022
  • FIGURE 25. HAEMONETICS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 26. HAEMONETICS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 27. HAEMONETICS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 28. MEDTRONIC PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. MEDTRONIC PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. MEDTRONIC PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. LIVANOVA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. LIVANOVA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. LIVANOVA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. FRESENIUS GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. FRESENIUS GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. FRESENIUS GROUP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. TERUMO INTERVENTIONAL SYSTEMS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. TERUMO INTERVENTIONAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. TERUMO INTERVENTIONAL SYSTEMS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. WANDONG HEALTH SOURCES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. WANDONG HEALTH SOURCES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. WANDONG HEALTH SOURCES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. REDAX S.P.A: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. REDAX S.P.A: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. REDAX S.P.A: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. GLOBAL BLOOD RESOURCES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. GLOBAL BLOOD RESOURCES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. GLOBAL BLOOD RESOURCES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. ATRIUM MEDICAL CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. ATRIUM MEDICAL CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. ATRIUM MEDICAL CORP.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. STRYKER CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. STRYKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. STRYKER CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Cardiopulmonary Auto-transfusion System Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers